Beyond the Scalpel: A New Post-Op Standard for Your Glioma Patients

Dear Colleagues,

You’ve performed a successful resection—now, let’s keep that surgical result stable for as long as possible. Based on the practice-changing data in the "INDIGO", we are shifting the paradigm from "Watch and Wait" to "Watch and Treat."

Here is why your Grade 2 IDH-mutant patients should be referred for Vorasidenib immediately following their surgery:

Don't Just Watch It Grow – Shrink It: While observation usually involves watching a tumor grow by an average of 13.9% every 6 months, Vorasidenib actively reverses this trend by shrinking tumor volume.

• 2.5x Longer Stability: Give your patients more time in the stable postoperative state you achieved. Vorasidenib offers a median progression-free survival of 27.7 months compared to just 11.1 months with observation alone.

• Fewer Seizures, Better Lives: Seizures are often the biggest hurdle for your patients returning to work. This therapy delivers a 64% reduction in seizure rates, drastically improving their daily independence and quality of life.

• A Massive "Treatment Gap": In the landmark INDIGO study, 80% of patients on this oral therapy did not require any further aggressive interventions for the duration of the study.

• Preserve Their Performance: This once-daily pill is specifically designed to cross the blood-brain barrier to maintain the high functional status and neurocognition your patients have post-surgery.

• The Takeaway: Referral within the early post-op window ensures we target the "driver" mutation before the disease progresses, keeping your patients stable, active, and out of the hospital.